Asia Pacific HIV Diagnostics Market, by Product Type (Instruments and Reagents & Kits), by Test Type (Screening {Third Generation and Fourth Generation}, Differentiation & Confirmation Test, and Monitoring Test {CD4 Tests and Viral Load Tests}), by End Us

Asia Pacific HIV Diagnostics Market, by Product Type (Instruments and Reagents & Kits), by Test Type (Screening {Third Generation and Fourth Generation}, Differentiation & Confirmation Test, and Monitoring Test {CD4 Tests and Viral Load Tests}), by End User (Hospitals and Clinics, Diagnostic Laboratories, Home Care Settings, and Others), and by Country (China, Japan, South Korea, ASEAN, India, Australia, and Rest of Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

HIV causes AIDS and interferes with the body's ability to fight infections. The virus can be transmitted through contact with infected blood, semen or vaginal fluids. Within a few weeks of HIV infection, flu-like symptoms such as fever, sore throat and fatigue can occur. Then the disease is usually asymptomatic until it progresses to AIDS. AIDS symptoms include weight loss, fever or night sweats, fatigue and recurrent infections. HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. HIV can be diagnosed through blood or saliva testing. Available tests include: Antigen/antibody tests. These tests usually involve drawing blood from a vein. Antigens are substances on the HIV virus itself and are usually detectable — a positive test — in the blood within a few weeks after exposure to HIV. According to the Center for Disease Control and Prevention, three types of HIV tests are available:

• Nucleic acid tests (NATs) — detects HIV ribonucleic acid (RNA)
• Antigen/antibody combination tests — detects HIV p24 antigen as well as HIV immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies
• Antibody tests — detects HIV IgM and/or IgG antibodies

The time between potential HIV exposure and an accurate test result is referred to as the window period. Improvements in testing technology continue to reduce the detection window period, and, therefore, the time to diagnosis and treatment of early HIV infection.

Market Dynamics

Increasing engagement programs by various government bodies to reduce disease burden of HIV epidemics and growing need for safe blood transfusion and donations in Asia Pacific is expected to drive the HIV diagnostic market size during the forecast period. For instance, in January 2018, India plans to make pre-exposure prophylaxis (PrEP) available to men who have sex with men (MSM) and transgender women. The Indian Council of Medical Research (ICMR) indicated in November 2018 that it is planning to study the effectiveness of PrEP in high-risk groups.

However, stigma and social ostracism associated with HIV infections and diseases is expected to hinder the timely HIV diagnostics and treatment. Moreover, the fear of being tested positive, discrimination, rejection, and stigma restricts several people from conducting screening voluntarily. The fear of discord in marital relationships is yet another challenge where testing HIV positive is often seen as a case of infidelity. Therefore, these factors are expected to hamper the market growth.

Key features of the study:

• This report provides an in-depth analysis of the Asia Pacific HIV diagnostics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Asia Pacific HIV diagnostics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Abbott Laboratories, Merck KGaA, F. Hoffmann-La Roche AG, Atomo diagnostics, Siemens Healthineers, Inc., bioLytical Laboratories Inc., MedMira Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., and Danaher Corporation
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Asia Pacific HIV diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Asia Pacific HIV diagnostics market

Detailed Segmentation:

• Asia Pacific HIV Diagnostics Market, By Product Type:
• Instruments
• Reagents & Kits
• Asia Pacific HIV Diagnostics Market, By Test Type:
• Screening
• Third Generation
• Fourth Generation
• Differentiation & Confirmation Test
• Monitoring Test
• CD4 Tests
• Viral Load Tests
• Asia Pacific HIV Diagnostics Market, By End User:
• Hospitals and Clinics
• Diagnostic Laboratories
• Home Care Settings
• Others
• Asia Pacific HIV Diagnostics Market, By Countries:
• Japan
• China
• South Korea
• ASEAN
• Australia
• India
• Company Profiles
• Abbott Laboratories*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Merck KGaA
• Hoffmann-La Roche AG
• Atomo Diagnostics
• Siemens Healthineers, Inc.
• BioLytical Laboratories Inc.
• MedMira Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Danaher Corporation

“*” marked represents similar segmentation in other categories in the respective section.